RxDoctor Payments DataLook up a doctor →

Monnieque Singleton, MD

Family Medicine · Orangeburg, SCNPI 1336193713

Payments from drug & device makers

$33,778in general payments, 2019–2025

Across 637 payments — averaging $53.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Novo Nordisk$4K
  • Novartis$3K
  • Lilly USA, LLC$957
  • Boehringer Ingelheim$693
  • Merck$662
  • plus $6K from 47 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Consulting fees$5,98934%
  • Travel & lodging$3422%
  • Food & beverage$10,91263%
  • Education$440%
  • Other$1291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,778 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$8,778
Medicare patients
255
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol287$232,177
JardianceEmpagliflozin250$203,462
OzempicSemaglutide162$176,756
MounjaroTirzepatide149$160,317
EntrestoSacubitril/Valsartan143$133,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter122$118,038
XareltoRivaroxaban93$84,768
JanuviaSitagliptin Phosphate80$77,040
EliquisApixaban85$69,350
LinzessLinaclotide90$63,356
Breztri AerosphereBudesonide/Glycopyr/Formoterol79$50,704
TrulicityDulaglutide39$37,942
KerendiaFinerenone48$36,100
Soliqua 100-33Insulin Glargine/Lixisenatide34$33,384
MyrbetriqMirabegron30$24,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$18,177$286,792383 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$693$223,435274 claims
Lilly USA, LLCMounjaro, Trulicity$957$198,259188 claims
Novo NordiskOzempic, Rybelsus$4,481$189,050173 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy$472$150,494222 claims
NovartisEntresto$2,913$133,078143 claims
MerckJanuvia, Janumet Xr, Janumet, Belsomra$662$104,122137 claims
Johnson & JohnsonXarelto$580$84,76893 claims
PfizerEliquis$339$69,35085 claims
AbbVieLinzess$166$63,35690 claims
BayerKerendia$662$36,10048 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$450$33,38434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →